These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 25641594)
1. Heterologous expression of carcinoembryonic antigen in Lactococcus lactis via LcsB-mediated surface displaying system for oral vaccine development. Zhang X; Hu S; Du X; Li T; Han L; Kong J J Microbiol Immunol Infect; 2016 Dec; 49(6):851-858. PubMed ID: 25641594 [TBL] [Abstract][Full Text] [Related]
2. Expression of the capsid protein of porcine circovirus type 2 in Lactococcus lactis for oral vaccination. Wang K; Huang L; Kong J; Zhang X J Virol Methods; 2008 Jun; 150(1-2):1-6. PubMed ID: 18406475 [TBL] [Abstract][Full Text] [Related]
3. Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination. Zhang Q; Zhong J; Huan L Microbiol Res; 2011 Feb; 166(2):111-20. PubMed ID: 20227266 [TBL] [Abstract][Full Text] [Related]
4. Heterologous protein display on the cell surface of lactic acid bacteria mediated by the s-layer protein. Hu S; Kong J; Sun Z; Han L; Kong W; Yang P Microb Cell Fact; 2011 Oct; 10():86. PubMed ID: 22035337 [TBL] [Abstract][Full Text] [Related]
5. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
6. Oral vaccine of Lactococcus lactis harbouring pandemic H1N1 2009 haemagglutinin1 and nisP anchor fusion protein elevates anti-HA1 sIgA levels in mice. Joan SS; Pui-Fong J; Song AA; Chang LY; Yusoff K; AbuBakar S; Rahim RA Biotechnol Lett; 2016 May; 38(5):793-9. PubMed ID: 26758876 [TBL] [Abstract][Full Text] [Related]
7. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Aarts WM; Schlom J; Hodge JW Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537 [TBL] [Abstract][Full Text] [Related]
8. Construction of a recombinant Lactococcus lactis strain expressing a fusion protein of Omp22 and HpaA from Helicobacter pylori for oral vaccine development. Zhang R; Duan G; Shi Q; Chen S; Fan Q; Sun N; Xi Y Biotechnol Lett; 2016 Nov; 38(11):1911-1916. PubMed ID: 27406731 [TBL] [Abstract][Full Text] [Related]
9. Oral immunization of mice with recombinant Lactococcus lactis expressing Cu,Zn superoxide dismutase of Brucella abortus triggers protective immunity. Sáez D; Fernández P; Rivera A; Andrews E; Oñate A Vaccine; 2012 Feb; 30(7):1283-90. PubMed ID: 22222868 [TBL] [Abstract][Full Text] [Related]
10. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
11. Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity. Berlec A; Malovrh T; Zadravec P; Steyer A; Ravnikar M; Sabotič J; Poljšak-Prijatelj M; Štrukelj B Appl Microbiol Biotechnol; 2013 May; 97(10):4333-42. PubMed ID: 23371298 [TBL] [Abstract][Full Text] [Related]
12. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Raha AR; Varma NR; Yusoff K; Ross E; Foo HL Appl Microbiol Biotechnol; 2005 Jul; 68(1):75-81. PubMed ID: 15635459 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644 [TBL] [Abstract][Full Text] [Related]
14. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267 [TBL] [Abstract][Full Text] [Related]
15. Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain. Parlane NA; Grage K; Lee JW; Buddle BM; Denis M; Rehm BH Appl Environ Microbiol; 2011 Dec; 77(24):8516-22. PubMed ID: 21984246 [TBL] [Abstract][Full Text] [Related]
16. Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+. Pereira VB; Saraiva TD; Souza BM; Zurita-Turk M; Azevedo MS; De Castro CP; Mancha-Agresti P; Dos Santos JS; Santos AC; Faria AM; Leclercq S; Azevedo V; Miyoshi A Appl Microbiol Biotechnol; 2015 Feb; 99(4):1817-26. PubMed ID: 25503506 [TBL] [Abstract][Full Text] [Related]
17. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice. Li D; Hua S; Fan Y; Xu S; Duan X; Liu L; Che Y; Li S; Tan Y Immunol Lett; 2011 Mar; 135(1-2):124-8. PubMed ID: 21073899 [TBL] [Abstract][Full Text] [Related]
18. Secretory expression of K88 (F4) fimbrial adhesin FaeG by recombinant Lactococcus lactis for oral vaccination and its protective immune response in mice. Hu CX; Xu ZR; Li WF; Niu D; Lu P; Fu LL Biotechnol Lett; 2009 Jul; 31(7):991-7. PubMed ID: 19277476 [TBL] [Abstract][Full Text] [Related]
19. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Grosenbach DW; Barrientos JC; Schlom J; Hodge JW Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081 [TBL] [Abstract][Full Text] [Related]
20. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]